ProQR Therapeutics' Price Target Reduced Amid Clinical Updates

Oppenheimer analyst Andreas Argyrides has reduced the price target for ProQR Therapeutics (PRQR) from $15 to $9, maintaining an Outperform rating. The firm highlighted ProQR's lead program, AX-0810, targeting cholestatic diseases, is on schedule for a Clinical Trial Application submission in Q2 2025. Despite strategic progress, ProQR faces challenges due to negative sector sentiment affecting early-stage clinical companies lacking clinical data. Oppenheimer has increased the discount rate from 30% to 40%.

Oppenheimer analyst Andreas Argyrides has revised the price target for ProQR Therapeutics (PRQR) from $15.00 to $9.00, a 40% decrease [1]. Despite this reduction, Oppenheimer has maintained its "Outperform" rating on the biotech company, reflecting continued confidence in its potential despite a revised financial outlook.

The adjustment reflects Oppenheimer's latest assessment of ProQR Therapeutics, which has faced challenges due to negative sector sentiment affecting early-stage clinical companies lacking clinical data. ProQR's lead program, AX-0810, targeting cholestatic diseases, is on schedule for a Clinical Trial Application submission in Q2 2025. However, the firm has increased its discount rate from 30% to 40% [1].

The average one-year price target from 9 analysts is $8.88, with a high estimate of $13.82 and a low estimate of $3.95. The consensus recommendation from 9 brokerage firms is currently 1.7, indicating an "Outperform" status [1]. Additionally, GuruFocus estimates the GF Value for ProQR Therapeutics to be $5.12, suggesting an upside of 223.03% from the current price of $1.585 [1].

Institutional investors have recently modified their holdings of the business. Jane Street Group LLC, Invesco Ltd., Alpine Global Management LLC, Two Sigma Securities LLC, and ADAR1 Capital Management LLC have bought new stakes in ProQR Therapeutics in the 4th quarter [2]. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics focuses on the discovery and development of novel therapeutic medicines, with products like AX-0810 for cholestatic diseases and AX-1412 for cardiovascular diseases [2].

References:
[1] https://www.gurufocus.com/news/2859394/proqr-therapeutics-prqr-price-target-lowered-by-oppenheimer-prqr-stock-news
[2] https://www.marketbeat.com/instant-alerts/fy2025-eps-forecast-for-proqr-therapeutics-cut-by-analyst-2025-05-14/